RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancerRegardless of whatever influenced ONCY's decision to target the HER2 failed breast cancer patient population, the HER2 failed population is a large and conclusively identifiable population since they are the same who had been previously identified as having HER2 (positive/negative) breast cancer, treated with an ADC therapy and then ultimately failing on this same therapy.
These failed breast cancer patients could benefit from the sequential introduction of ONCY's pelareorep with the ADC and then an immune checkpoint inhibitor.